That amazing news, hopefully this is released to the gen public soon.

I was being optimistic when I said soon, I don't know for sure when this would be released. I just going by what was posted and hoped in a year as I too have tried other remedies with no success.

Adz888 wrote:
Its a long wait guys.
Hey Terry,
Thanks for taking time out in your work to respond, it is greatly appreciated. Last question, purely on your guesswork only, when do you think a product would be developed around?
Regards
Adam

Dear Adam,
Based on our development plan, this product will available in Asian market during 2015.
All the best
Terry
Pharmacist of Regulatory affairs
Uni Pharma Co., Ltd.
:(

I went to the link. From my understanding of it... I shows that Convivia is still on phase 2 and is available for Partnering(corporations). This means the product is not yet available to the general public.

Hi Everyone, There has not been much update since I have last logged on. I figured I would be the first to response since the last message received by Splotchy. Unfortunate to here that it will be 2015 that this will be released. On the other hand there is a proposed released and it is coming soon! If any one has a update on this, please share it I'm sure it would be much appreciated.

has anyone tried af formula? checked out the site, looked kinda scetchy kind of reminds me of "no red face" scam...

Great work MTER! Keep us posted on any updates.

Posted on Raptor Quarterly report:

"Convivia(TM) is our proprietary oral formulation of 4-methylpyrazole, or 4-MP, intended for the potential treatment of acetaldehyde toxicity resulting from alcohol consumption in individuals with ALDH2 deficiency, which is an inherited disorder of the body's ability to breakdown ethanol, commonly referred to as alcohol intolerance. 4-MP is presently marketed in the US and E.U. in an intravenous form as an anti-toxin. Convivia(TM) is designed to lower systemic levels of acetaldehyde (a carcinogen) and reduce symptoms, such as tachycardia and flushing, associated with alcohol consumption by ALDH2-deficient individuals. Convivia(TM) is a capsule designed to be taken approximately 30 minutes prior to consuming an alcoholic beverage.

In 2008, we completed a Phase 2a dose escalation clinical trial of oral 4-MP with ethanol in ALDH2 deficient patients. The study results demonstrated that the active ingredient in Convivia(TM) significantly reduced heart palpitations (tachycardia), which are commonly experienced by ALDH2 deficient people who drink, at all dose levels tested. The study also found that the 4-MP significantly reduced peak acetaldehyde levels and total acetaldehyde exposure in a subset of the study participants who possess specific genetic variants of the liver ADH and ALDH2 enzymes. We believe that this subset represents approximately one-third of East Asian populations.

In June 2010, we entered into an exclusive agreement with Uni Pharma Co., Ltd., or Uni Pharma to commercialize Convivia(TM) in Taiwan. Under terms of the agreement, we will grant to Uni Pharma an exclusive license under all relevant . . ."

Any word on the release date? another year without any new updates, still on phase 2...

is there any update? There is no news on raptors pharma's site. Anyone from korea?

Did anyone get any news or updates?

There will always be a way to get it in north america. we've gotta get support, keep sending those emails.

Yeah i got the same answer. That is actually the exactly same email I got I sent 2 weeks ago.